DRUG STUDY: NCM 106 PHARMACOLOGY Instructor: _______________________________________ Date: ________________________

NAME: ____________________________________________________________ BLOCK and Year:___________________________Group: ______________________________

DRUG NAME MECHANISM OF INDICATION CONTRAINDICATION ADVERSE EFFECTS NURSING

ACTION INTERVENTIONS
Competes with natural Chronic HBV infection with Hypersensitivitytodrugorits  CNS: headache, Patient monitoring:
substrate deoxyguanosine evi- dence of active viral components dizziness, fatigue  Monitor renal
Generic Name: triphosphate to inhibit HBV replication and either  GI: nausea, diarrhea, function before and
Enteclavir polymerase (reverse persistent serum transaminase dyspepsia, increased during therapy,
transcriptase) elevations or histologically GI enzymes especially in liver
active disease  Hematologic: transplant recipients
hematuria who are receiving or
 Hepatic: HBV have received
exacerbation, severe immune suppressants
Drug Classification: hepatomegaly that may affect renal
antiviral  Metabolic: function. 2Monitor
glycosuria, lactic liver function closely
acidosis for evidence of HBV
exacerbation for at
least several months
after drug
discontinuation.
Available Dosage:  Monitor for lactic
 DOSAGE TABLET: acidosis (associ- ated
0.5mg with nucleoside
1mg analogues).
 ORAL SOLUTION;  Patient teaching
0.05mg/ml Instruct patient to take
drug on empty
stomach (at least 2
hours before or after a
meal).
 Teach patient about
signs and symptoms
of lactic acidosis and
importance of
contacting prescriber
if these occur.
 Instruct patient to
immediately report
worsening symptoms,
 such as increased
yellowing of skin or
eyes, dark urine, or
fatigue.
 As appropriate,
review all other
significant and life-
threatening adverse
reactions and
interactions,
especially those
related to the drugs
and tests mentioned
above.